Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShort-Term Debt repayments
Ratios

Cue Biopharma (CUE) Leases (2019 - 2025)

Cue Biopharma's Leases history spans 7 years, with the latest figure at $4.6 million for Q3 2025.

  • For Q3 2025, Leases rose 14.08% year-over-year to $4.6 million; the TTM value through Sep 2025 reached $4.6 million, up 14.08%, while the annual FY2024 figure was $4.4 million, 30.89% down from the prior year.
  • Leases for Q3 2025 was $4.6 million at Cue Biopharma, down from $5.1 million in the prior quarter.
  • Across five years, Leases topped out at $9.9 million in Q2 2022 and bottomed at $369000.0 in Q4 2022.
  • The 5-year median for Leases is $5.6 million (2024), against an average of $6.0 million.
  • The largest annual shift saw Leases crashed 96.24% in 2022 before it surged 1613.55% in 2023.
  • A 5-year view of Leases shows it stood at $9.8 million in 2021, then plummeted by 96.24% to $369000.0 in 2022, then soared by 1613.55% to $6.3 million in 2023, then plummeted by 30.89% to $4.4 million in 2024, then increased by 5.31% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Leases are $4.6 million (Q3 2025), $5.1 million (Q2 2025), and $3.6 million (Q1 2025).